years organisms need test limit cost effectiveness added blood borne diseases months not years blood positive reaction disease question hardly feasible test blood donor donation possible pathogen pre emptive treatment new technology hold promise pre emptive technique pathogen reduction involves treating donated blood eliminate possibility infection range microorganisms targeting known disease individually currently france poland spain switzerland united kingdom compounds riboflavin vitamin b2 methylene blue combination light inactivate known pathogens platelets blood plasma development artificial blood blood components reduce risk infection tainted blood types synthetic coagulation factors main therapeutic components fresh frozen plasma use years artificial red blood cells synthetic